Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05534971 · ClinicalTrials.gov registry record · Phase 4
Central Line Study
A Phase 4 study of Shock, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT05534971: Recruiting Phase 4 study of Shock, sponsored by Montefiore Medical Center.
NCT05534971 is a Phase 4 study of Shock that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 160 participants, below the 464-participant average among 9 other Shock trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05534971, a Phase 4 study of Shock, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Two different techniques for placing a central venous catheter will be compared. The studyu team hypothesizes that clinicians randomized to the peripheral catheter technique will have higher first attempt success rates, fewer procedural complications, and a shorter mean time to procedure completion than physicians assigned to wire through hollow bore needle.
Primary Outcome
The frequency with which the central line can be placed with only one attempt will be summarized. Each attempt is defined by skin penetration
Conditions Studied
Interventions
- PROCEDURE Central venous catheter insertion
Study Locations (1)
New York
- Montefiore - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
What NCT05534971 shows while recruiting
NCT05534971 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 464-participant average among 9 other Shock trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Shock appearing as the primary indexed condition, and to 1 intervention - of which Central venous catheter insertion is the first listed.
NCT05534971 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05534971 about?
NCT05534971 is a clinical study titled "Central Line Study". Two different techniques for placing a central venous catheter will be compared. The studyu team hypothesizes that clinicians randomized to the peripheral catheter technique will have higher first attempt success rates, fewer procedural complications, and a shorter mean time to procedure completion ...
What is the current status of trial NCT05534971?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2022-11-16. Estimated completion is 2027-12.
What conditions does trial NCT05534971 study?
This clinical trial studies the following conditions: Shock.
What interventions are being tested in trial NCT05534971?
The interventions under investigation include: Central venous catheter insertion (PROCEDURE).
Who is sponsoring clinical trial NCT05534971?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05534971 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05534971's enrollment target sits among peer trials
160 5th of 9 higher than 5 of 9 other Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vasoactive Drugs in Intensive Care Unit
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Effect of Nebulized Bronchodilators on Heart Rate
COMPLETED · Phase 4
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
-
Resuscitative TEE Collaborative Registry
RECRUITING
-
Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI